Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Clinical Trials2
• Diabetic Retinopathy2
• Retina2
• DME1
• Anti-vegf1
• Diabetic Eye Disease1
• Inherited Retinal Disease1
• Partnership1
• Retinal Vein Occlusion (rvo)1
• Technology1

• Organizations: Kodiak Sciences✕

Clear all

Pipeline

Kodiak Sciences concludes enrollment for phase 3 DR on tarcocimab

Anti-VEGF tarcocimab tedromer is under clinical investigation as a mainstay IVT monotherapy with twice-yearly dosing for three retinal indications.

Pipeline

Nona Biosciences and Kodak Sciences to advance antibody therapies for ophthalmic diseases

Kodiak to further develop retinal disease asserts via Nona’s Harbour Mice platform, designed to generate fully human monoclonal antibodies at half the size of regular IgG.

Pipeline

Kodiak is restarting its tarcocimab clinical program for three retinal disease indications

Just 3 months after discontinuing tarcocimab tedromer for DME, new phase 3 data may support an indication for diabetic retinopathy.